Source:

Press Release

August 05, 2020
1 min read
Save

Regenxbio reports positive results of phase 1/2a RGX-314 trial

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Regenxbio will initiate a pivotal program for subretinal delivery of RGX-314 in patients with wet age-related macular degeneration later this year, following the release of positive 1-year data from a phase 1/2a trial.

The company plans to advance to AAVIATE, a phase 2 trial of the drug, with patient enrollment beginning in the third quarter, according to a press release.

The phase 1/2a trial evaluated 42 patients with severe wet AMD who required frequent anti-VEGF injections. In five cohorts, the doses ranged from 3 × 109 GC per eye to 2.5 × 1011 GC per eye.

Generally, all cohorts tolerated RGX-314 well, with 18 serious adverse events reported in 11 patients, 17 of which were not related to the drug. The one event that may have been drug related involved a significant decrease in vision in a patient experiencing retinal pigmentary changes involving the macula.

Nonserious adverse events included postoperative conjunctival hemorrhage in 69% of patients, postoperative inflammation in 36%, eye irritation in 17%, eye pain in 17% and postoperative visual acuity reduction in 17%.

Patients in cohort 4 and 5 had stable visual acuity with an average change in best corrected visual acuity of +4 letters and –2 letters, respectively, from baseline. Retinal thickness decreased by an average of –61 µm and –79 µm, respectively. Both cohorts had a significant reduction in anti-VEGF treatment burden compared with the previous 12 months. Cohort 4 had a 61% reduction in anti-VEGF injections, while cohort 5 had an 85% reduction.

Regenxbio plans to announce interim data from AAVIATE by the end of the year. AAVIATE is a multicenter, open-label, randomized, active-controlled, dose-escalation study measuring efficacy, safety and tolerability of the suprachoroidal delivery of RGX-314.